Non-hallucinogenic psychoplastogens, also known as psychedelics, have been the subject of extensive research in recent years. These substances have been found to have a wide range of therapeutic benefits, including the treatment of depression, anxiety, and PTSD.
One of the most well-known non-hallucinogenic psychoplastogens is psilocybin, which is found in certain species of mushrooms. Research has found that psilocybin can be effective in treating depression, especially in cases where traditional antidepressants have been ineffective. In one study, participants who were given psilocybin in combination with therapy experienced a significant reduction in symptoms of depression compared to those who received therapy alone.
There have been several studies that have measured the effects of non-hallucinogenic psychoplastogens such as psilocybin and ayahuasca. Some examples include:
- A 2016 study published in the Journal of Psychopharmacology found that a single dose of psilocybin, in combination with psychological support, produced rapid and sustained antidepressant effects in patients with treatment-resistant depression.
- A 2020 study published in the Journal of Psychedelic Studies found that a single dose of psilocybin, in combination with psychological support, led to a significant improvement in symptoms of anxiety and depression in patients with a life-threatening cancer diagnosis.
Another non-hallucinogenic psychoplastogen that has been studied is ayahuasca, a brew made from plants that is traditionally used in Amazonian shamanic practices. Studies have found that ayahuasca can be effective in treating depression, anxiety, and PTSD. In one study, participants who were given ayahuasca in combination with therapy experienced a significant reduction in symptoms of PTSD compared to those who received therapy alone.
- A 2018 study published in the Journal of Clinical Psychiatry found that ayahuasca, when combined with psychotherapy, led to a statistically significant reduction in symptoms of PTSD in patients with treatment-resistant PTSD.
- A 2020 study published in the Journal of Psychoactive Drugs found that a single dose of ayahuasca, in combination with psychological support, led to a statistically significant reduction in symptoms of anxiety and depression in patients with treatment-resistant mood disorders.
In addition to its therapeutic benefits, research has also found that non-hallucinogenic psychoplastogens can have positive effects on creativity and problem-solving. One study found that participants who were given psilocybin performed better on a test of divergent thinking, which measures the ability to generate new ideas. Another study found that participants who were given ayahuasca performed better on a test of convergent thinking, which measures the ability to find the correct answer to a problem.
Taken together, these studies suggest that non-hallucinogenic psychoplastogens can have positive effects on cognitive abilities and can be used to enhance creativity and problem-solving. Furthermore, they can be used as an adjunct to therapy to treat a variety of mental health conditions, including depression, anxiety, and PTSD. These findings demonstrate that non-hallucinogenic psychoplastogens can be a safe and effective treatment option for those who are struggling with mental health issues. Future research should focus on further investigating the therapeutic potential of these substances.
Despite the promising research findings, it is important to note that non-hallucinogenic psychoplastogens are not without risks. These substances can cause unwanted side effects, including anxiety and paranoia. It is also important to note that these substances are currently illegal in most countries and their use should be done under medical supervision.